Related Experiment Video

Updated: Jun 29, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

Pediatric HCT in Florida (2014 -2016): A report from the FPBCC

Deepak Chellapandian1, Gauri Sunkersett1, Benjamin Oshrine1

  • 1Blood and Marrow Transplant Program, Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.

Pediatric Transplantation
|November 27, 2020
PubMed

Insights

Florida pediatric blood and marrow transplant (BMT) centers identified HLA match as key to survival in children undergoing allogeneic BMT. Improving donor selection and death reporting are crucial for better outcomes.

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Transplantation Immunology

Background:

  • The Florida Pediatric Blood and Cancer Consortium (FPBCC) was established in 2018 by five pediatric transplant programs.
  • A primary goal is to analyze outcomes by consolidating data from participating centers to identify improvement areas.

Purpose of the Study:

  • To describe patient and transplant characteristics of pediatric patients undergoing their first allogeneic (allo-HCT) and autologous (auto-HCT) hematopoietic stem cell transplants in Florida between 2014 and 2016.
  • To identify predictors of survival in pediatric HCT recipients.

Main Methods:

  • Data were sourced from the CIBMTR's eDBtC database.
  • Analysis of patient and transplant characteristics for pediatric allo-HCT and auto-HCT recipients.

Main Results:

  • A total of 230 pediatric allo-HCT and 104 auto-HCT procedures were performed.
  • For malignant disorders, HLA match was the most significant predictor of survival in allo-HCT.
  • For non-malignant disorders, age, donor relationship, and HLA match predicted survival in allo-HCT recipients.

Conclusions:

  • The degree of HLA match is a critical factor for survival in pediatric allo-HCT.
  • Enhancing the reporting of primary causes of death and optimizing donor selection are necessary.
  • This FPBCC-wide review confirms the feasibility of using a collaborative approach and data platform for improving pediatric HCT outcomes.

Keywords:
Florida consortiumoutcomespediatric HCT

More Related Videos

Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity10:14

Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity

Published on: December 17, 2013

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...